Aim. To analyze the anti-inflammatory efficacy of Regasthym Gastro (alpha-glutamyl-tryptophan) in the treatment of patients with chronic atrophic gastritis according to endoscopic and morphometric studies. Materials and methods. As part of a double-blind placebo-controlled study, the results of gastroscopy and histological (morphometric) studies were retrospective analyzed in 80 patients diagnosed with chronic atrophic gastritis associated with Helicobacter pylori in exacerbation: 43 patients took Regasthym Gastro, 37 patients placebo. The conclusions of the gastroscopy were structured in the form of a standardized scale, which included an assessment of criteria in points (from 0 to 3): thickness of folds, hyperemia, edema of the gastric mucosa, the signs of atrophy, metaplasia; the severity of the erosive process. The sum of points according to all criteria was used to assess the dynamics of the inflammatory process: positive dynamics; lack of dynamics; the pathological process is progressing. The results of the endoscopic examination were compared with morphometry data (the number of inflammation pool cells per 1 mm2 of gastric mucosa). Statistical processing of the results was carried out using the Statistica 12 application software package. Results. According to the gastroscopy, before therapy, hyperemia of the gastric mucosa was present in 82.5%, edema in 53.8%, erosion in 17.5%, signs of metaplasia in 12.5% of patients. After therapy with the investigated drug a statistically significant decrease in the severity of edema of the gastric mucosa (p=0.008), the total set of signs of acute inflammatory process (p=0.006), a decrease in the proportion of outcomes with negative dynamics of the inflammatory process (p=0.038) was revealed. Statistically significant (p0.05) correlations were found between gastroscopy data of inflammation and the number of neutrophil, eosinophil granulocytes, macrophages and lymphocytes per 1 mm2. Conclusion. Regasthym Gastro contributes to a significant decrease in the severity of the inflammatory process according to the evaluation of the results of gastroscopy and morphometry. It is possible to recommend the inclusion of this drug in the complex therapy of chronic gastritis to increase the effectiveness and reduce the risks of progression of inflammation.
30 August 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
Introduction. The COVID-19 pandemic has stimulated the search for drugs with specific antiviral activity against the new pathogenic strain of the SARS-CoV-2 coronavirus. First of all, scientific search was aimed at studying drugs with already proven efficacy against influenza and ARVI.The aim of this workwas to study the antiviral activity of Cytovir®-3in vitroin relation to the cytopathogenic effect of the SARS-CoV-2 virus.Material and methods.The antiviral activity of the drug Cytovir®-3 against the SARS-CoV-2 virus was studied in experimental modelsin vitroon Vero CCL81 cell culture (ATCC). The maximum tolerated concentration and the 50% cytotoxic dose were determined using a quantitative microculture tetrazolium test assay to calculate the working range of the concentrations of the test drug.Results and discussion.As a result of the study, it was shown that the greatest activity of the drug was manifested when it was added to the cells 24 hours before and 1 hour and 24 hours after viral infection, the inhibition level reached 53% (>IC50) at the drug concentrations of 105, 55, and 85 µg/ml, respectively. Cytovir®-3 suppressed the viral activity of SARS-CoV-2 in the dose range from 10 µg/ml to 105 µg/ml under the indicated infection conditions. It was found that the drug did not exhibit cytotoxic effects on the Vero cell culture in the range of antiviral doses.Conclusion.The antiviral activity of Cytovir®-3 against the SARS-CoV-2 virus has been proven due to the achievement of IC50, which is below the maximum tolerated dose of 149 µg/ml.
30 August 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
On account of the COVID-19 pandemic, the global pharmaceutical industry has achieved impressive results in the development and introduction of various types of vaccines causing the formation of acquired immunity against the SARS-CoV-2 coronavirus into clinical practice. However, none of them currently show the declared one hundred percent guarantee of protection. In the case of the COVID-19 disease, patients with concomitant pathologies are the most vulnerable to the occurrence of severe complications. The aerosol route of transmission of SARS-CoV-2 contributes to the emergence of outbreaks of the new coronavirus infection in crowded places and closed rooms with poor ventilation. In this regard, an urgent problem is the search for drugs with local antiviral activity, which, together with restrictive measures and mask wearing policy, can potentially reduce the likelihood of contracting coronavirus. In this experimental in vitro study on Vero CCL81 cell culture (ATCC), the local antiviral activity of the drug Thymogen® spray against the SARS-CoV-2 virus was studied in comparison with the antiseptic Miramistin® solution. As a result of the experiment, no toxic effects on Vero cells were detected in the drugs in the studied concentrations. In a series of experiments, Thymogen® spray showed local antiviral activity against SARS-CoV-2 when the virus titer was 5,2 lg TCID50. Therefore, the drug Thymogen® dosed nasal spray has high potential as a topical drug for prevention and treatment of COVID-19 disease, which requires additional confirmation in relevant clinical studies.
Influenza and acute respiratory viral infections (ARVI) have a high prevalence, which determines their clinical and economic relevance. Agents activating nonspecific antiviral immunity mechanisms can be used to prevent these infections. Objective. To perform a systematic review and meta-analysis of the results of clinical studies on the preventive antiviral effectiveness of the three-drug regimen (alpha-glutamyl-tryptophan, bendazole, and ascorbic acid) against influenza and acute respiratory viral infections. Materials and methods. Following the PRISMA guidelines, the results of controlled clinical studies on the preventive effectiveness of the three-drug regimen (alpha-glutamyl-tryptophan, bendazole, and ascorbic acid) were selected using the recommended databases. The effectiveness was evaluated based on serum levels of total and stimulated interferon, serum and salivary immunoglobulin A levels, and oxidative and phagocytic activity of granulocytes and monocytes. The risk of bias and the quality of studies were assessed using the RoB 2 tool. The meta-analysis was conducted using the Meta package of the R statistical software and included an assessment of the generalized differences in the mean values of the parameters before and after the treatment course (Z-test), an assessment of the fixed/random weight of the studies, and verification of their heterogeneity (I2 test). Results. The results of four clinical studies, published between 2018 and 2021, were selected. A statistically significant (generalized) treatment effect size was identified for induced oxidative activity of granulocytes (an increase of 2.18 standard deviations; p=0.0004; I2=87.2%); salivary IgA levels (an increase of 0.73 standard deviations; p=0.0001; I2=86.6%); phagocytic activity of monocytes (an increase of 1.39 standard deviations; p=0.0001; I2=90.9%); phagocytic activity of granulocytes (an increase of 0.85 standard deviations; p=0.0031; I2=82.7%). Conclusion. The studied treatment regimen demonstrated an adaptive-activating effect on various elements of innate antigen-nonspecific immunity, contributing to the prevention of influenza and acute respiratory viral infections.
3 October 2025 in Russian Journal of Evidence-Based Gastroenterology
Chronic autoimmune atrophic gastritis is one of the key risk factors for the development of gastric malignancies. Objective: To describe a clinical case illustrating the dynamics of long-term structural changes in the gastric mucosa in the absence of treatment and following therapy with alpha-glutamyl-tryptophan. Clinical case. A chronological account is presented detailing the diagnosis, treatment, clinical features, and histological findings from gastric mucosal biopsies in a 57-year-old patient, monitored from 2020 to 2025. Conclusion. This clinical case demonstrates the potential of alpha-glutamyl-tryptophan as a course-based therapy for the early and timely management of structural changes in the gastric mucosa associated with chronic autoimmune atrophic gastritis.